journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/28417657/a-kissing-lesion-in-vivo-7t-evidence-of-meningeal-inflammation-in-early-multiple-sclerosis
#1
Pierre Kolber, Amgad Droby, Alard Roebroeck, Rainer Goebel, Vinzenz Fleischer, Sergiu Groppa, Frauke Zipp
BACKGROUND: The role of cortical lesions (CLs) in disease progression and clinical deficits is increasingly recognized in multiple sclerosis (MS); however the origin of CLs in MS still remains unclear. OBJECTIVE: Here, we report a para-sulcal CL detected two years after diagnosis in a relapsing-remitting MS (RRMS) patient without manifestation of clinical deficit. METHODS: Ultra-high field (7T) MR imaging using magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE) sequence was performed...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28417656/in-vivo-imaging-of-meningeal-inflammation-in-multiple-sclerosis-presence-of-evidence-or-evidence-of-presence
#2
Iris D Kilsdonk, Menno Schoonheim, Mike P Wattjes
No abstract text is available yet for this article.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28406354/human-endogenous-retroviruses-and-multiple-sclerosis-causation-association-or-after-effect
#3
Elena Morandi, Rachael E Tarlinton, Radu Tanasescu, Bruno Gran
From the early days of MS discovery, infections have been proposed as a possible cause of the disease. In the last three decades, an association between human endogenous retrovirus expression and MS has been further investigated and confirmed. Nevertheless, the role of such retroviruses in the disease needs clarification. In this review, we introduce MSRV/HERV-W and describe its association with MS. We then summarize the evidence for the involvement of MSRV/HERV-W in the aetiology and progression of MS and its possible role as biomarker and drug target...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28406063/metabolites-predict-lesion-formation-and-severity-in-relapsing-remitting-multiple-sclerosis
#4
Antoine M Klauser, Oliver T Wiebenga, Anand Jc Eijlers, Menno M Schoonheim, Bernard Mj Uitdehaag, Frederik Barkhof, Petra Jw Pouwels, Jeroen Jg Geurts
BACKGROUND: Multiple sclerosis is characterized by white matter lesions, which are visualized with conventional T2-weighted magnetic resonance imaging (MRI). Little is known about local metabolic processes preceding the appearance and during the pathological development of new lesions. OBJECTIVE: To identify metabolite changes preceding white matter (WM) lesions and pathological severity of lesions over time. METHODS: A total of 59 relapsing-remitting multiple sclerosis (MS) patients were scanned four times, with 6-month intervals...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28401769/the-diagnostic-dilemma-of-multiple-sclerosis-presenting-with-isolated-cognitive-and-behavioral-disorders
#5
Maria Pia Amato
Cognitive and behavioral symptoms are common in multiple sclerosis (MS), even from the early stages of the disease, but they are considered to be rarely the inaugural and predominant manifestation of the disease, thus jeopardizing early and accurate diagnosis. This clinical commentary highlights a number of peculiar characteristics that should be taken into consideration in case of primary cognitive/neuropsychiatric dysfunction and white matter lesions of unclear origin, in order to prompt appropriate diagnostic workup...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28401768/primary-progressive-multiple-sclerosis-presenting-with-severe-predominant-cognitive-impairment-and-psychiatric-symptoms-a-challenging-case
#6
Alberto Andrea Zambon, Giordano Cecchetti, Francesca Caso, Roberto Santangelo, Cristina Baldoli, Maria Grazia Natali Sora, Giancarlo Comi, Giuseppe Magnani, Vittorio Martinelli
Severe cognitive dysfunction is a frequent feature of multiple sclerosis (MS), normally associated with later stages of the disease in adult population. Nevertheless, progressive cognitive and neuropsychiatric disturbances might rarely be the presenting and predominant symptom. In order to better characterize this peculiar phenotype of MS, we report on the case of a 38-year-old man who referred to our hospital with the suspect of hereditary leukodystrophy after 5 years of behavioral and mood abnormalities, global cognitive dysfunction, clumsiness, and very mild pyramidal and cerebellar signs...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28397579/secondary-paroxysmal-dyskinesia-in-multiple-sclerosis-clinical-radiological-features-and-treatment-case-report-of-seven-patients
#7
Ethel Ciampi, Reinaldo Uribe-San-Martín, Jaime Godoy-Santín, Juan Pablo Cruz, Claudia Cárcamo-Rodríguez, Carlos Juri
Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS). Carbamazepine is effective, but with risk of adverse reactions. We identified 7 patients with SPD among 457 MS patients (1.53%). SPD occurred in face ( n = 1), leg ( n = 2), or arm +leg ( n = 4) several times during the day. Magnetic resonance imaging (MRI) showed new or enhancing lesions in thalamus ( n = 1), mesencephalic tegmentum ( n = 1), and cerebellar peduncles ( n = 5)...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28397578/paroxysmal-kinesigenic-dyskinesia-like-phenotype-in-multiple-sclerosis
#8
Roxana Pop, Stefan Kipfer
In April 2015, a 20-year-old woman with multiple sclerosis (MS) presented with acute onset of repetitive abnormal postures and choreatic movements of the right arm, precipitated by voluntary movements (online video 1 and 2). Brain magnetic resonance imaging (MRI) showed a new active MS lesion involving the basal ganglia on the left side (Figure 1(a)). Intravenous steroid treatment resulted in rapid regression of this paroxysmal kinesigenic dyskinesia (PKD)-like hyperkinetic movement disorder. The patient became asymptomatic within 3 months...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28397577/clinical-commentary-on-paroxysmal-kinesigenic-dyskinesia-like-phenotype-in-multiple-sclerosis-and-secondary-paroxysmal-dyskinesia-in-multiple-sclerosis-clinical-radiological-features-and-treatment-case-report-of-seven-patients
#9
Isabel Pareés
This clinical commentary discusses the phenomenology and treatment of paroxysmal dyskinesia in patients with multiple sclerosis. It calls for a consensus on the definition as well as for larger studies to better understand this unusual clinical association.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28394203/dysregulation-of-energy-metabolism-in-multiple-sclerosis-measured-in-vivo-with-diffusion-weighted-spectroscopy
#10
Benedetta Bodini, Francesca Branzoli, Emilie Poirion, Daniel García-Lorenzo, Mélanie Didier, Elisabeth Maillart, Julie Socha, Geraldine Bera, Catherine Lubetzki, Itamar Ronen, Stephane Lehericy, Bruno Stankoff
OBJECTIVE: We employed diffusion-weighted magnetic resonance spectroscopy (DW-MRS), which allows to measure in vivo the diffusion properties of metabolites, to explore the functional neuro-axonal damage and the ongoing energetic dysregulation in multiple sclerosis (MS). METHODS: Twenty-five patients with MS and 18 healthy controls (HC) underwent conventional magnetic resonance imaging (MRI) and DW-MRS. The apparent diffusion coefficient (ADC) of total N-acetyl-aspartate (tNAA) and creatine-phosphocreatine (tCr) were measured in the parietal normal-appearing white matter (NAWM) and in the thalamic grey matter (TGM)...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28394195/composite-mri-measures-and-short-term-disability-in-patients-with-clinically-isolated-syndrome-suggestive-of-ms
#11
Giulia Bommarito, Alessandro Bellini, Matteo Pardini, Claudio Solaro, Luca Roccatagliata, Alice Laroni, Elisabetta Capello, Giovanni Luigi Mancardi, Antonio Uccelli, Matilde Inglese
BACKGROUND: The use of composite magnetic resonance imaging (MRI) measures has been suggested to better explain disability in patients with multiple sclerosis (MS). However, little is known about the utility of composite scores at the earliest stages of the disease. OBJECTIVE: To investigate whether, in patients with clinically isolated syndrome (CIS), a composite MRI measure, rather than the single metrics, would explain conversion to MS and would better correlate with disability at baseline and at 1 year of follow-up...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28391741/unexpected-exacerbations-following-initiation-of-disease-modifying-drugs-in-neuromyelitis-optica-spectrum-disorder-which-factor-is-responsible-anti-aquaporin-4-antibodies-b-cells-th1-cells-th2-cells-th17-cells-or-others
#12
Jun-Ichi Kira
Some disease-modifying drugs for multiple sclerosis, which mainly act on T cells, are ineffective for neuromyelitis optica spectrum disorder and induce unexpected relapses. These include interferon beta, glatiramer acetate, fingolimod, natalizumab, and alemtuzumab. The cases reported here suggest that dimethyl fumarate, which reduces the number of Th1 and Th17 cells and induces IL-4-producing Th2 cells, is also unsuitable for neuromyelitis optica spectrum disorder, irrespective of anti-aquaporin 4 IgG serostatus...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28391740/catastrophic-relapses-following-initiation-of-dimethyl-fumarate-in-two-patients-with-neuromyelitis-optica-spectrum-disorder
#13
Bassem I Yamout, Shawkat Beaini, Maya M Zeineddine, Nabil Akkawi
We report two cases of neuromyelitis optica spectrum disorder (NMOSD) who were misdiagnosed as multiple sclerosis (MS) and developed catastrophic relapses following initiation of dimethyl fumarate. Both patients developed a severe myelitis extending from the cervical cord to the medulla with significant cord swelling, resulting in complete quadriplegia and respiratory difficulties, in addition to severe bilateral visual loss in one patient. It is of note that both catastrophic relapses occurred 2 and 3 months following initiation of dimethyl fumarate...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28385128/retrograde-trans-synaptic-visual-pathway-degeneration-in-multiple-sclerosis-a-case-series
#14
Omar Al-Louzi, Julia Button, Scott D Newsome, Peter A Calabresi, Shiv Saidha
BACKGROUND: Trans-synaptic degeneration (TSD) describes the propagation of neuronal injury through synaptic pathways in the human nervous system and may be linked to the accelerated retinal atrophy seen in multiple sclerosis (MS). RESULTS: We report six cases where homonymous, hemi-macular ganglion cell + inner plexiform (GCIP) thickness reduction was seen in conjunction with posterior visual pathway lesions. Macular microcystoid changes of the inner nuclear layer (INL) were seen in a subset of three subjects...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28385089/commentary-on-retrograde-trans-synaptic-visual-pathway-degeneration-in-ms-a-case-series
#15
Ahmed Toosy
No abstract text is available yet for this article.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28382837/long-term-disability-trajectories-in-primary-progressive-ms-patients-a-latent-class-growth-analysis
#16
Alessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Dana Horakova, Eva Havrdova, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, Pierre Grammond, Murat Terzi, Bhim Singhal, Raed Alroughani, Thor Petersen, Cristina Ramo, Celia Oreja-Guevara, Daniele Spitaleri, Vahid Shaygannejad, Helmut Butzkueven, Tomas Kalincik, Vilija Jokubaitis, Mark Slee, Ricardo Fernandez Bolaños, Jose Luis Sanchez-Menoyo, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Gerardo Iuliano, Stella Hughes, Roberto Bergamaschi, Bruce Taylor, Freek Verheul, Maria Edite Rio, Maria Pia Amato, Seyed Aidin Sajedi, Nastaran Majdinasab, Vincent Van Pesch, Maria Pia Sormani, Maria Trojano
BACKGROUND: Several natural history studies on primary progressive multiple sclerosis (PPMS) patients detected a consistent heterogeneity in the rate of disability accumulation. OBJECTIVES: To identify subgroups of PPMS patients with similar longitudinal trajectories of Expanded Disability Status Scale (EDSS) over time. METHODS: All PPMS patients collected within the MSBase registry, who had their first EDSS assessment within 5 years from onset, were included in the analysis...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28381133/randomized-controlled-trial-of-a-home-based-palliative-approach-for-people-with-severe-multiple-sclerosis
#17
Alessandra Solari, Andrea Giordano, Francesco Patti, Maria Grazia Grasso, Paolo Confalonieri, Lucia Palmisano, Michela Ponzio, Claudia Borreani, Rosalba Rosato, Simone Veronese, Paola Zaratin, Mario Alberto Battaglia
BACKGROUND: Evidence on the efficacy of palliative care in persons with severe multiple sclerosis (MS) is scarce. OBJECTIVE: To assess the efficacy of a home-based palliative approach (HPA) for adults with severe MS and their carers. METHODS: Adults with severe MS-carer dyads were assigned (2:1 ratio) to either HPA or usual care (UC). At each center, a multi-professional team delivered the 6-month intervention. A blind examiner assessed dyads at baseline, 3 months, and 6 months...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28381130/pilot-trial-of-intravenous-autologous-culture-expanded-mesenchymal-stem-cell-transplantation-in-multiple-sclerosis
#18
Jeffrey A Cohen, Peter B Imrey, Sarah M Planchon, Robert A Bermel, Elizabeth Fisher, Robert J Fox, Amit Bar-Or, Susan L Sharp, Thomai T Skaramagas, Patricia Jagodnik, Matt Karafa, Shannon Morrison, Jane Reese Koc, Stanton L Gerson, Hillard M Lazarus
BACKGROUND: Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest. OBJECTIVE: To assess feasibility, safety, and tolerability and explore efficacy of autologous MSC transplantation in MS. METHODS: Participants with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), Expanded Disability Status Scale score 3...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28381105/-no-evident-disease-activity-the-use-of-combined-assessments-in-the-management-of-patients-with-multiple-sclerosis
#19
Gavin Giovannoni, Davorka Tomic, Jeremy R Bright, Eva Havrdová
Using combined endpoints to define no evident disease activity (NEDA) is becoming increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS). Historically, NEDA has taken account of the occurrence of relapses, brain magnetic resonance imaging (MRI) lesions and disability worsening, but this approach places emphasis on inflammatory activity in the brain and mostly overlooks ongoing neurodegenerative damage. Combined assessments of NEDA which take account of changes in brain volume or neuropsychological outcomes such as cognitive function may begin to address this imbalance, and such assessments may also consider blood or spinal-fluid neurofilament levels or patient-reported outcomes and quality of life measures...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28367678/comparing-costs-of-illness-of-multiple-sclerosis-in-three-different-years-a-population-based-study
#20
Hanna Gyllensten, Michael Wiberg, Kristina Alexanderson, Emilie Friberg, Jan Hillert, Petter Tinghög
BACKGROUND: Little is known about changes in the costs of illness (COI) among multiple sclerosis (MS) patients during recent years. OBJECTIVES: To compare the COI among MS patients and matched controls in 2006, 2009, and 2012, respectively, indicating the costs attributable to the MS disease. METHODS: Three cross-sectional datasets were analyzed, including all MS patients in Sweden aged 20-60 years and five matched controls for each of them...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"